Search

Your search keyword '"Aulakh, Sonikpreet"' showing total 135 results

Search Constraints

Start Over You searched for: Author "Aulakh, Sonikpreet" Remove constraint Author: "Aulakh, Sonikpreet"
135 results on '"Aulakh, Sonikpreet"'

Search Results

4. VISTA Emerges as a Promising Target against Immune Evasion Mechanisms in Medulloblastoma.

8. Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patients

9. RTID-08. A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY WITH ANTISENSE OLIGO IMV-001 TARGETING IGF-1R, VS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS

11. Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patients.

12. Capicua (CIC) mutations in gliomas in association with MAPK activation for exposing a potential therapeutic target

16. PATH-22. CLINICAL FEATURES AND MOLECULAR CHARACTERIZATION OF LEPTOMENINGEAL DISEASE IN PATIENTS WITH HIGH GRADE GLIOMA

19. The Roadmap to Pituitary in COVID-19 Crisis

22. Capicua (CIC) mutations in gliomas in association with MAPK activation for exposing a potential therapeutic target.

24. Biological and prognostic relevance of epigenetic regulatory genes in high-grade gliomas (HGGs).

26. Abstract PO-104: Disparity in race and age reporting in landmark cancer clinical trials: Underrepresentation of the traditionally underserved U.S. population

28. Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age Reporting

30. Modulation of the blood-tumor barrier to enhance drug delivery and efficacy for brain metastases

35. Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses

37. Contributors

39. Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia

44. Disparity in Clinical Trial Opportunities for Patients with B-Cell Malignancies in the United States

45. Computational Modelling of Multiple Myeloma Patient Genomic Signatures to Predict Treatment Outcome

46. Timeliness of Initial Therapy in Multiple Myeloma (MM): Trends and Factors Influencing Patient Care

47. Trends in the Risk of Second Primary Malignancies (SPMs) Among Survivors of Chronic Lymphocytic Leukemia(CLL)

49. EXTH-06. CD38-TARGETED THERAPY IN GLIOBLASTOMA

50. Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells

Catalog

Books, media, physical & digital resources